Session 13 – Advances in Cancer Immunotherapy
Date: 24 July (Friday) 14:00 – 15:30 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform
Mien-Chie Hung, Ph.D. is the President for China Medical University in Taichung, Taiwan. He was vice president for basic research and professor and chair of the Department of Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer Center from 2010-2019. Dr. Hung is a basic scientist with a keen translational vision and especially his recent research effort has significantly contributed to understanding the biology of cancer and to developing combinational cancer therapies to overcome resistance. Up to date, Dr. Hung has published more than 540 peer-reviewed articles, of which over 135 were published in journals with impact factor 10 or above. His lifetime h-index surpasses 115. He is one of members of Selection Committee for Tang Prize in Biopharmaceutical Science category and is one of the founding Editorial Members for Cancer Cell, serves as Editor-in-chief for American Journal for Cancer Research (2015-2017) and Senior Editor for Cancer Research (American Association for Cancer Research, 2018-2021). Dr. Hung was inducted as an Academician of the Academia Sinica in Taiwan in 2002 and as a Fellow in Biological Sciences section, American Association for the Advancement of Science in 2010. His laboratory has a long term commitment to the following research areas: 1) discovery of novel functionality of epidermal growth factor receptor (EGFR) family which may provide useful insight to understand cancer formation and development; 2) identification of crosstalks of signal pathways/networks in cancer cells and tumor microenvironment which could potentially predict resistance to target therapy; 3) development of marker-guided targeted therapy including PARP and EGFR inhibitors, immune checkpoint therapy which will effectively treat cancer patients.
Speech title & Synopsis
Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising therapeutics for many diseases, including cancer. We showed that combination of c-Met and PARP1 inhibitors synergized to suppress growth of breast cancer cells in vitro and xenograft tumor models (Nature Medicine 22:194-201, 2016). We are working with clinicians at MD Anderson and initiate clinical trials using combinational therapy of PARP and c-MET inhibitors.
Anti-PD-1/PD-L1 therapy is a promising approach in cancer therapy. We showed that glycosylation of PD-L1 is required for its protein stability and interaction with PD-1 (Nature Communications 7:12632, 2016). Furthermore, we developed effective combination therapy by metformin-activated AMPK kinase to downregulates PD-L1 through alteration of glycosylation of PD-L1 and (Molecular Cell 71:606, 2018). We also identified two mechanisms in HCC to develop effective combination therapy with immunotherapy (Gastroenterology 156:1849, 2019, & JCI 129:3324, 2019). We identified TNFα as a major factor triggering cancer cell immunosuppression against T cell surveillance via stabilization of programmed cell death-ligand 1 (PD-L1) (Cancer Cell 30:925, 2016). To this end, in collaboration with StCube Pharmaceuticals Inc., we have developed monoclonal antibodies against glycosylation-specific PD-L1. Impressive therapeutic effect was observed through antibody-drug-conjugate approach (Cancer Cell 33: 187, 2018 & Cancer Res 80:2298, 2020). If time allows, this talk will include our recent discoveries on developing therapies for lung or pancreatic cancers. (Cancer Cell 34:9549, 2018 & Cancer Cell 33:752, 2018), a new methodology to retrieve antigen by protein deglycosylaton improves predictive ability of PD-L1 as a biomarker for immunotherapy. (Cancer Cell 36:168, 2019). Furthermore, I will cover our recent exciting study unravels the importance of the protein kinase activity of PCK1 in the activation of SREBPs, lipogenesis and the development of HCC; and identifies the inhibition of the protein kinase activity of PCK1 as a potential treatment strategy in HCC (Nature 580:530, 2020).